Comparative Pharmacology
Head-to-head clinical analysis: OGESTREL 0 5 50 28 versus ORTHO NOVUM 7 14 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGESTREL 0 5 50 28 versus ORTHO NOVUM 7 14 21.
OGESTREL 0.5/50-28 vs ORTHO-NOVUM 7/14-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
None Documented
None Documented
Norgestrel: ~45 hours (range 24-56 h) enabling once-daily dosing; Ethinyl estradiol: ~17 hours (range 10-27 h).
Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norgestrel and ethinyl estradiol); Fecal: 30-40% via biliary elimination; Unchanged drug: <1%.
Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor
Category C
Category C
Oral Contraceptive
Oral Contraceptive